$TELA

TELA Bio reported Q3 2026 revenue of $19.0M, down 8% YoY, and a net loss of $9.3M. Gross profit was $12.3M (64.9% margin). Adjusted EBITDA loss improved to $3.4M. The company reduced operating loss by 21% and implemented cost-cutting measures. International revenue grew 18% YoY, and the company gained market share in its hernia portfolio. TELA Bio also received 510(k) clearance for a new product and regained Nasdaq compliance.

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Third Quarter 2026 Financial Results Reduced sequential operating loss by 21%, including cost of realignment MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a comme rcial-stage medical technology company focused on providing innovative

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2026, TELA Bio, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “ Special Meeting ”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstandin

TELA Bio has regained compliance with Nasdaq's minimum bid price requirement, according to a notification received on Oct 5, 2026. The company's common stock continues to trade under the symbol TELA. This compliance ensures TELA Bio's continued listing on the Nasdaq Global Market.

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, TELA Bio, Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq L

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TELA Bio Announces 510(k) Clearance for Liora TM Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissu

TELA Bio (NASDAQ: TELA) received FDA 510(k) clearance for its Liora Monofilament Scaffold, a resorbable surgical mesh for soft tissue reinforcement. The product, developed in-house, expands the company's portfolio and market presence. Details will be discussed during the upcoming Q3 earnings call in November.

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, TELA Bio, Inc. (the “ Company ”) entered into a Limited Consent to Credit Agreement and Guaranty (the “ Limited Consent ”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral ag

Capper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.18 ($1.17–$1.22) across 2 trades over 2026-09-16 to 2026-09-17.

Capper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.05 ($1.02–$1.06) across 2 trades over 2026-09-14 to 2026-09-15.